EFSA Approves Folate Claim for Neural Tube Defects
Panel also issues dosage recommendations.
The EFSA Panel on Dietetic Products, Nutrition, and Allergies has decreed that there is sufficient scientific evidence to support the benefit of maternal folate supplementation as it relates to reducing the risk of neural tube defects in infants. In addition, the panel recommended a daily dose of 400 μg of folate for at least one month before and up to three months after conception.
The decision came as the result of a filing from Rank Nutrition Ltd. (Kent, UK), an independent nutrition science consultancy.
The EFSA decision comes some 15 years after the U.S. FDA’s recognition of the connection between folate supplementation and neural tube defects and the subsequent fortification of grain-based products with folic acid-a move that contributed to the reduction of American neural tube birth defects by about 36% (Centers for Disease Control).
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Steve Mister on CRN's ongoing lawsuit against New York State
October 11th 2024Nutritional Outlook spoke to The Council for Responsible Nutrition's president and CEO, Steve Mister, at its annual meeting, Convergence '24. Mister discussed the latest in its ongoing lawsuit against NY State's law banning the sale of weight management and muscle building products to minors.
